Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436).
K. L. Nathanson
Research Funding - GlaxoSmithKline
A. Martin
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
R. Letrero
No relevant relationships to disclose
K. P. D'Andrea
No relevant relationships to disclose
S. O'Day
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
J. R. Infante
No relevant relationships to disclose
G. S. Falchook
Research Funding - GlaxoSmithKline
Other Remuneration - GlaxoSmithKline
M. Millward
Research Funding - GlaxoSmithKline
C. M. Curtis
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
B. Ma
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
R. C. Gagnon
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
P. F. Lebowitz
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
G. V. Long
Consultant or Advisory Role - GlaxoSmithKline (U)
R. F. Kefford
Consultant or Advisory Role - GlaxoSmithKline
Other Remuneration - GlaxoSmithKline